1. Home
  2. XNCR vs PVLA Comparison

XNCR vs PVLA Comparison

Compare XNCR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xencor Inc.

XNCR

Xencor Inc.

N/A

Current Price

$33.57

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

N/A

Current Price

$143.53

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XNCR
PVLA
Founded
1997
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
XNCR
PVLA
Price
$33.57
$143.53
Analyst Decision
Buy
Strong Buy
Analyst Count
14
17
Target Price
$43.83
★ $233.44
AVG Volume (30 Days)
★ 1.5M
231.4K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 65.36
52.62
EPS
★ N/A
N/A
Revenue
★ $125,576,000.00
$42,810,000.00
Revenue This Year
$58.19
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
13.65
★ 65.28
52 Week Low
$10.38
$72.23
52 Week High
$40.60
$179.95

Technical Indicators

Market Signals
Indicator
XNCR
PVLA
Relative Strength Index (RSI) 54.03 46.38
Support Level $22.80 $139.09
Resistance Level $33.60 $158.60
Average True Range (ATR) 2.08 10.44
MACD -0.54 -2.18
Stochastic Oscillator 35.21 7.56

Price Performance

Historical Comparison
XNCR
PVLA

About XNCR Xencor Inc.

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: